Visterra, Inc. Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains With Pandemic Potential

Published: Sep 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., developer of novel therapeutics to treat major infectious diseases, today announced that its Chief Medical Officer, Donna Ambrosino, M.D., presented data on VIS410 at the Options for the Control of Influenza, an international conference held every three years, taking place this year in Cape Town, South Africa on September 5-9, 2013. The preclinical data presented at the Options conference showed broadly protective properties of VIS410 as an effective preventive and therapeutic investigational agent against influenza A subtypes. In the preclinical study, VIS410 had an additive effect when used in combination with anti-viral drugs in the treatment of influenza. These data build on the body of existing studies that have shown the efficacy of VIS410 against a broad range of influenza A strains, including H1N1, H5N1 and H3N2. Developed using Visterra’s innovative technology, VIS410 is designed to be a broadly protective, fully human monoclonal antibody that targets a site on influenza hemagglutinin (HA) that is present across all influenza A subtypes, and is resistant to mutation.

Help employers find you! Check out all the jobs and post your resume.

Back to news